Pimavanserin: A 2019 Clarification on the FDA Update

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

To the Editor: It was with great interest that we read the letter to the editor titled "Pimavanserin for Parkinson Disease Psychosis" by Mohanty et al published in The Primary Care Companion for CNS Disorders. This letter discusses Parkinson disease psychosis (PDP) including the clinical features, pathophysiology, and treatments such as quetiapine, clozapine, and the recently introduced antipsychotic, pimavanserin. Although Mohanty and colleagues provide a thorough overview of pimavanserin’s mechanism of action and pharmacokinetics, we would like to elaborate on their discussion of pimavanserin’s safety considerations.